

25 MARCH 2024

BREAKTHROUGH DISTRIBUTION DEAL

Ticker INC

Share price 9.8p
Market cap £9.0m

Share price performance 1 yr



Source: Aquis

Company description

Founded as a spin-out from the Institute of Centre Therapeutics at the University of Bradford in 2010, Incanthera is a UK-based specialist in dermatological cancer treatments. Products include a UV cream, Sol, to prevent skin cancer development, and a targeted drug delivery vector for cancer cells designed to improve treatment and minimise side effects. The latest product development, *Skin+CELL*, is a high-end cosmetic designed to deliver Vitamin B3 niacinamides which promote dermatological health and cell regeneration.

Board & Management

Chairman - Tim McCarthy

CEO - Dr Simon Ward

CFO - Laura Brogden

Company Secretary - Suzanne Brocks

Stanford Capital Partners
Research

Mike Jeremy
+44 (0) 20 3650 3650
mjeremy@stanfordcp.co.uk

Corporate Broking
Bob Pountney
+44 (0) 20 3650 3651
bpountney@stanfordcp.co.uk

On 18th December 2023 Incanthera announced a deal with Marionnaud in Switzerland to distribute '*Skin+CELL*', its advanced dermatological solution for the delivery of vitamin B3 for skin protection and cosmetic rejuvenation. This gives Incanthera access to a high-end cosmetics distribution presence in Europe, and in addition, ownership of Marionnaud by AS Watson, the largest cosmetics distributor in Asia, offers significant new market opportunities further afield.

Incanthera has developed topical (skin cream) methods for delivering B3 (an activated form of niacinamide) and other cosmetic compounds, which enhance dermatological health and repair, directly into the skin's cells to optimise cellular health, energy and protective capabilities.

Its Skin+CELL products appeal to the high-end cosmetic market-demand for skin care that offers anti-aging and protective properties.

The purpose of this exercise is to demonstrate the scale of the opportunity Incanthera addresses, i.e. the combination of the appeal of *Skin+CELL* in the pharma-cosmetics market niche plus the distribution relationships Incanthera has developed with the Watson Group.

- Under the terms of the deal *Skin+CELL* will be available initially in c.100 of Marionnaud's stores in Switzerland and Austria from Q2 2024, offering the opportunity for staff to familiarise with the product and marketing approach. This will be followed by roll out to Marionnaud's remaining 1,100 stores across European markets from 2024 onwards.
- To meet initial demand, Incanthera will supply 50,000 units, via the Swiss manufacturer Frike Cosmetic A.G. Incanthera has allocated to Frike full responsibility for the manufacturing, packaging and quality control of its skincare product range for international retail contracts. Based in central Switzerland, Frike manufactures a wide range of cosmetic and healthcare products for major brands across Europe, providing services from lab testing and production to assembly, warehousing and distribution.

Subsequently, there is the opportunity to distribute *Skin+CELL* into major Asian markets, backed by strong consumer appetite for skincare and health and beauty products – especially those carrying the imprimatur of Swiss branding – via A.S. Watson's strong retail presence with c.7,600 outlets in Asia: China (3,836 stores), Malaysia, Thailand and the Philippines, out of a total of 16,142.

In this report we assess the potential financial impact of what **Chairman Tim McCarthy has called a "truly transformational deal for the company"**¹. Our hypothetical impact study suggests two scenarios:

- **Scenario 1.** Initial distribution via the Marionnaud network of c.1,200 outlets in Switzerland, Austria and across Europe, with successful take-up leading to increased momentum of product profile and customer interest. This indicates the potential to generate initial annual revenue in year 1 of c.£10m, growing to c.£33m in year 2.
- **Scenario 2.** Take-up throughout the A.S. Watson Group of c.8,000 distributors in China and Asia. The impact of broadened distribution takes year 3 revenue above the £90m level.

Fund raise. On 18 December the company announced a fundraise of £1.0m (gross) for the launch of *Skin+CELL*, comprising £0.8m for 11,428,571 shares at 7.0p/share and conversion of £0.2m by the University of Bradford (2,857,143 shares).

¹ Proactive Investors interview, 11th January 2024.

INCANTHERA – DEVELOPMENT PATH

SPIN-OUT ORIGINS

Incanthera was founded in 2010 a spin-out from the University of Bradford Institute of Cancer Therapeutics (ICT), which itself was established in 2005, with the aim of identifying, developing and commercialising novel technologies in its field; oncology and dermatology. The initial focus of Incanthera was on the targeted novel drug delivery of cytotoxins to treat cancers in a process of development to delivery and out-licensing. The company has made a series of acquisitions:

- **2011**, acquisition of EP0015 from the ICT projects pipeline.
- **2014**, acquisition of Onco-NX (Equin programme), Duo C technology (ICT pipeline) and Spear Therapeutics Ltd., (Duo-C programme).
- **2015/16**, acquisition of EP0015 a theranostic (therapeutic/diagnostic) from the ICT pipeline and a taxane from the ICT pipeline, for the identification (in conjunction with PET scanning) and targeted treatment of lung, breast, ovarian and prostate cancers.
- **2018**, acquisition from Limeway Pharma Design of the rights to *Sol*, a skin cream designed to treat sun-damaged skin (solar keratoses) and prevent the development of skin cancers by enhancing natural dermatological defences to UV radiation (patented in 2020).

SKIN+CELL KEY TECHNOLOGY: B3 DELIVERY

Following the conclusion of a commercial deal for the initial distribution of Incanthera's *Skin+Cell* cosmetic skin treatment we assess potential financial impact through a range of scenarios.

Incanthera has developed technologies which are effective in delivering bioactive B3 (active niacinamide compounds) through the dermal barrier directly. A range of cosmetic formulations will be marketed as *Skin+CELL*. Vitamin B3 (niacin) acts as coenzyme for c.400 enzymes important for the nervous and digestive systems, and skin. The aim of Incanthera's B3 delivery technology is to enhance skin health and repair, improve skin tone and add protection. It is therefore attractive as a cosmetic with pharmaceutical properties.

As illustrated, human skin as an organ consists of eight principal layers, the outer four or five of which, (the stratum compactum) form the protective epidermis. The uppermost, outer layer of the epidermis consists of c.25-30 layers of flattened dead lower level keratinocytes which have been transformed into corneocytes – keratin packages without a nucleus or internal organelles – akin to a 'chain mail' protective barrier but with cells which are continuously shed. This barrier, resistant to water loss and chemically difficult to penetrate, is impervious to proteins, sugars, peptide and nucleic acids with molecular weights above 100kDa² (1 Da (1 Dalton), is equal to one hydrogen molecular atom, 1g/mol. An amino acid has an average molecular weight of 110Da).


Studies indicate some success in the use of retinoids, kinetin, soy protease, green teas (camellia senensis) and niacinamides in the treatment of skin damage and as 'anti-aging' agents, reducing damage from sun exposure and removing pigmentation and wrinkles. Niacinamide – specifically niacinamide adenosine dinucleotide (NAD) and niacinamide adenosine dinucleotide phosphate (NADP) - serves to reduce oxidation in a number (c.40) of cellular reactions, with benefits for skin health and appearance, including improved skin structure leading to reduced fine lines and wrinkles, or reduced yellowing resulting from protein oxidation (Maillard reaction). Early studies³ indicated the possibility of percutaneous skin penetration. This is the key property for which Incanthera offers a solution.

Incanthera has developed the technology to deliver niacinamide compounds past the skin's barrier layers through topical application.

² Journal of Clinical and Aesthetic Dermatology, 3-02-2020 J Levin and S Momin, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921764>.

³ Feldmann RJ, Maibach HI. *Absorption of some organic compounds through the skin in man.* J Invest Dermatol. 1970;54:399-404.

Incanthera's technologies deliver compounds for cellular skin health and repair



Source: theory.labster.com.

Commercial launch of *Skin+CELL* initially in Switzerland and Austria, and subsequently across a wider European footprint followed by development of marketing in Asia.

KEY DISTRIBUTION DEAL

On 18 December 2023 Incanthera announced a commercial deal to launch of *Skin+CELL* as a luxury skincare brand with Marionnaud Switzerland & Austria, part of the A.S. Watson Group, the Hong Kong-based international health, beauty, and lifestyle brand retailer with 16,100 stores serving 5.3bn customers across 28 markets. The A.S. Watson Group is owned by the international conglomerate CK Hutchison Holdings (mkt cap £14.8bn). Specifically:

- *Skin+CELL* will be available initially in 100 of Marionnaud's stores in Switzerland and Austria from Q2 2024, followed by roll out to its remaining 1,100 stores across European markets from 2024 onwards.
- To meet initial demand from Switzerland and Austria, Incanthera will supply 50,000 units, via the Swiss manufacturer Frike Cosmetic A.G. Frike has assumed responsibility for the manufacturing, packaging and quality control of Incanthera's skincare product range for international retail contracts.
- Subsequent distribution is planned for Asia, backed by consumer appetite for skin-care and health and beauty products, and A.S. Watson's strong retail presence.

The Marionnaud deal will be managed through Skin and Cell AG, a wholly-owned Incanthera subsidiary based in Switzerland, formed specifically for the worldwide product promotion and distribution.

ESTIMATED MARKET OPPORTUNITY

The deal with Marionnaud gives Incanthera access to broad market presence and links with larger partner organisations:

- As noted, initial access via c.100 Marionnaud outlets in Switzerland and Austria to enable product familiarisation.
- Subsequent access to Marionnaud's network of c.1,100 branches and outlets in the rest of Europe.
- Planned access to A.S. Watson's network of retail outlets. Via its ownership of Watson Group Hutchison has an extensive retail presence across China, Malaysia, Thailand, Philippines and Turkey. As Hutchison notes in its 2022 AR (p30): "Watsons is the leading health and beauty retail chain in Asia with strong brand name recognition and extensive geographical coverage". Watson's brand presence includes: Kruidvat and Trekpleister in the Netherlands, Rossmann GmbH (4,000 outlets), Superdrug (UK), savers (UK economy health and home beauty), Drogas (Latvia, Lithuania), ICI Paris XL (cosmetics in

Netherlands, Belgium, Luxembourg) and The Perfume Shop (UK and Ireland with 215 outlets and an online presence).

Excluding discount retail outlets we estimate the Watson connection offers the opportunity to access a distribution network totalling over 16,000 stores in 28 markets.




Source: Hutchison Group AR 2022.

BUSINESS MODEL: SALES AND SUPPLY DISTRIBUTION NETWORK

As illustrated below, Incanthera has established a production, distribution and sales network across Europe and, via A.S. Watson, into Asia and the Far East. Incanthera plc (UK) licences *Skin+CELL* production via *Skin+CELL* AG, a 100%-owned Swiss subsidiary, for sales distribution initially across Europe, via Marionnaud and latterly via the Watson network.

- Initial phase distribution in Switzerland and Austria: c. 50,000 units.
- Subsequent (Scenario 1) across Europe: c.250,000 units, increasing to 1.0m units p.a.
- Expansion in into Asia, Far East and RoW: >3.0m units p.a. (Scenario 2).

Incanthera retains the right to commercial discussions for potential licensing deals with other organisations in all other global territories outside of those in which Watson Group has geographical exclusivity to *Skin+CELL*.



Source: Company data.

QUANTIFYING THE *SKIN+CELL* OPPORTUNITY

HYPOTHETICAL IMPLICATIONS

We present a series of entirely hypothetical revenue development scenarios for the distribution of *Skin+CELL* across a series of European and Asian geographies.

Positioning as a luxury cosmetic would be aided by 'Swiss' branding in the important process of establishing a 'must have' niche in the skincare marketplace and building market presence momentum. This might include approval by increasingly important online influencers or adoption by personality opinion formers.

The key elements of the *Skin+CELL* opportunity are: complete satisfaction on the part of distribution partner Marionnaud in the product efficacy and manufacture to the highest standards by Frike Cosmetic AG and positioning as a luxury cosmetic. We outline one possible progression as:

- **Scenario 1.** Successful roll-out across c.1,200 Marionnaud outlets in Switzerland, Austria and Europe, with successful take-up leading to an increased momentum of product profile and customer interest, and active marketing. The estimated FY25 potential revenue is c.£10m, increasing to c.£33m in FY26, steadily increasing further in subsequent years.
- **Scenario 2.** Wider product take-up throughout the A.S. Watson Group of distributors in China and Asia.

These scenarios are the product of a comparatively straightforward process of projection within sales and distribution networks which are well-established in terms of both market presence and operational systems.

We do not consider that *Skin+CELL* has to 'displace' popular skin cream brands such as Clarins, as it is positioned as a pharma-cosmetic which occupies a unique niche in the product ranges offered by Incanthera's sales and distribution partners. This also sets *Skin+CELL* apart from products in the 'wellness' or 'herbal remedy' market segment.

CONCLUSION

As noted, the purpose of this exercise is to demonstrate the scale of the opportunity Incanthera addresses: the combination of the appeal of *Skin+CELL* in the pharma-cosmetics market niche plus the distribution relationships Incanthera has developed with the Watson Group. Scenario 1 outlines the immediate opportunity presented in the current FY; Scenario 2 maps out the full potential in prospect.

Skin+CELL potential revenue pathway scenarios Financial Year ended March 31

| Scenario 1 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|-----------------------|---------|---------|-----------|-----------|-----------|------------|
| Av. unit price (£) | 34 | 35 | 35 | 35 | 35 | 35 |
| Stores | 1,200 | 1,200 | 1,200 | 1,200 | 1,200 | 1,200 |
| Units/store/wk | 5 | 15 | 17 | 19 | 20 | 21 |
| Units sold | 300,000 | 936,000 | 1,060,800 | 1,185,600 | 1,248,000 | 1,310,400 |
| Revenue £m | 10.1 | 32.8 | 37.1 | 41.5 | 43.7 | 45.9 |
| Estimated EBIT margin | 27.0% | 30.0% | 33.0% | 36.0% | 36.0% | 36.0% |
| Scenario 2 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| Av. unit price (£) | 34 | 35 | 35 | 35 | 35 | 35 |
| Stores | 1,200 | 1,200 | 3,000 | 5,000 | 8,000 | 10,000 |
| Units/store/wk | 5 | 15 | 17 | 19 | 20 | 21 |
| Units sold | 300,000 | 936,000 | 2,652,000 | 4,940,000 | 8,320,000 | 10,920,000 |
| Revenue £m | 10.1 | 32.8 | 92.8 | 172.9 | 291.2 | 382.2 |
| Estimated EBIT margin | 27.0% | 30.0% | 33.0% | 36.0% | 36.0% | 36.0% |

Source: Stanford Capital Partners estimates.

SUMMARY FINANCIAL DATA

Below summarises Incanthera's financial position as of the 30 September 2023, FY24, Interim, subsequent to which, on 18 December 2023, the company raised £1.0m (gross).

| Financial summary FY22 to H1 24 | | | |
|------------------------------------|---------|----------|----------|
| Yr to March 31 (£m) | FY22 | FY23 | H1 24 |
| Revenue | 0.000 | 0.000 | 0.000 |
| Sum Op-ex | (0.937) | (0.811) | (0.587) |
| One-off costs | (0.148) | (0.149) | (0.028) |
| EBIT Adjusted | (0.937) | (0.811) | (0.587) |
| EBITDA Reported | (1.085) | (0.960) | (0.615) |
| EBITDA Adjusted | (0.937) | (0.811) | (0.587) |
| PBT Reported | (1.085) | (1.447) | (0.615) |
| PAT Reported | (1.008) | (1.372) | (0.615) |
| Operating Cash Flow | (0.818) | (0.818) | (0.587) |
| Cash generated by operations | (0.769) | (0.528) | (0.105) |
| Net OpFCF | (0.662) | (0.453) | (0.105) |
| Share issue | 0.000 | 0.161 | 0.098 |
| Net increase in cash / equivalents | (0.662) | (0.292) | (0.007) |
| Cash at beginning of year | 0.957 | 0.295 | 0.003 |
| Cash at year end | 0.295 | 0.003 | (0.004) |
| Sum Fixed Assets | 0.540 | 0.059 | 0.059 |
| Sum Current Assets | 0.488 | 0.138 | 0.102 |
| Sum Current Liabilities | (0.196) | (0.280) | (0.633) |
| Sum Long-term liabilities | 0.000 | (0.131) | (0.195) |
| Net Assets | 0.832 | (0.214) | (0.667) |
| Share Capital | 1.482 | 1.528 | 1.556 |
| Share Premium | 5.055 | 5.169 | 5.239 |
| Reserves | 3.954 | 4.122 | 4.186 |
| Retained earnings | (9.659) | (11.033) | (11.648) |
| Equity | 0.832 | (0.214) | (0.667) |

Source: Company data.

APPENDIX I: BOARD

TIM MCCARTHY - NON-EXECUTIVE CHAIRMAN

Tim has 40 years' international senior level business experience in the Healthcare, Biotech and Technology sectors. He is CEO of ImmuPharma plc an AIM quoted specialist drug discovery and development company and Chairman of 4basebio PLC, an AIM quoted company developing next generation gene therapy technologies and solutions. Tim is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies.

Tim is a Fellow of the Association of Chartered Certified Accountants, and has an MBA from Cranfield School of Management

DR SIMON WARD - CHIEF EXECUTIVE OFFICER

Simon is a co-founder of Incanthera and has more than 30 years' senior experience in academia and business. He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market.

Simon graduated from the University of London's School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.

LAURA BROGDEN – CHIEF FINANCIAL OFFICER

Laura Brogden has 20 years' experience heading up the finance function for SMEs across a diverse range of industries. She is a Partner in Fact3 LLP which provides accounting, HR and IT support for SMEs.

Laura is an Associate of the Chartered Institute of Management Accountants.

SUZANNE BROCKS – HEAD OF COMMUNICATIONS, COMPANY SECRETARY

Suzanne has over 30 years' City experience.

She was a Senior Director in Financial and Corporate Communications with Buchanan Communications, advising on IPOs and mergers and acquisitions, in addition to general financial public relations consultancy and strategic direction for a wide range of public companies. Previously Suzanne was a Relationship Manager in private banking with Hill Samuel advising clients in London and the Far East.

CAROLINE MURRAY – NON-EXECUTIVE DIRECTOR

Caroline's work across healthcare, market positioning and strategic implementation brings extensive product management, and marketing and commercialisation experience to the Board. Over the course of 30 years senior positions held in the pharmaceutical industry, including Novartis and Bristol Myers Squibb, have combined expertise in dermatology and healthcare with commercial experience.

DISCLAIMER

This report was commissioned by **Incanthera PLC** and has been prepared and distributed for information purposes only by Stanford Capital Partners Limited ("SCP"). SCP receives a fixed fee from **Incanthera PLC** for the production and distribution of this report. The report is a marketing communication and should not be relied upon as being an impartial or objective assessment of the subject matter and does not constitute investment research for the purposes of the Conduct of Business Sourcebook ("COBS") issued by the Financial Authority ("FCA") to reflect the requirements of the UK retained version of Regulation 600/2014/EU and the UK retained version of Directive 2014/65/EU and all rules made in connection therewith (together, known as "MIFID II"). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector. Accordingly, this report has not been prepared in accordance with legal requirements designed to promote the independence of investment research under MIFID II or otherwise and is not subject to any prohibition on dealing ahead of the dissemination of investment research. SCP may from time to time render advisory and other services to companies referred to in this report and may receive compensation for the same.

Neither the information in this report nor any opinion expressed in this report constitutes an offer by SCP to enter into any contract/agreement, nor is it a solicitation to buy or sell any investment. Nothing in this report should be deemed to constitute the provision of financial, investment or other professional advice in any way.

The content of this report is based upon sources of information believed to be reliable, however, save to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to its accuracy, completeness or correctness and SCP, its officers and employees do not accept any liability or responsibility in respect of the information or any views expressed herein or for any direct or consequential loss arising from any use of the information contained in the report.

This report may include forward-looking statements that are based upon current opinions, expectations and projections and they are not a reliable indicator of future performance. SCP undertakes no obligation to update or revise any forward-looking statements. Any references to past performances in this report are not indicative of future performance or results. Investments in general involve some degree of risk, including the risk of capital loss. The services, securities and investments discussed in this document may not be available to or suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment advisor. The value of any investment referred to in this report may go down as well as up and any amounts recovered may be less than those originally invested. When SCP comments on AIM shares investors should be aware that because the rules for this market is less demanding than the Official List of the London Stock Exchange the risks are higher. Furthermore, the marketability of these shares is often restricted.

This report has been designed for, is directed at and for distribution only to persons who (i) fall within article 19(1) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in COBS (issued by the FCA) of SCP (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied upon by persons in the United Kingdom who are not relevant persons and should not be distributed, in whole or in part, to any third party without the prior written consent of SCP.

Neither this report, nor any copy or part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform him or herself about and observe any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of securities laws in the United Kingdom, the United States (or any part thereof) or any other jurisdiction in any other part of the world.

SCP and/or its associated companies may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to SCP that is not reflected in this material and SCP may have acted upon or used the information prior to or immediately following its publication. In addition, SCP, directors, and employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives, or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this material may be duplicated in any form or by any means.

Stanford Capital Partners Limited (FRN:804552) is registered in England and Wales (No 11192616) a member of the London Stock Exchange and Regulated by the Financial Conduct Authority.

Dissemination of Research: reports are made available to all relevant recipients at the same time. Issuers may, in certain circumstances, be permitted to review investment analysts' investment research prior to publication for review of factual accuracy only. Investment research prepared and disseminated by SCP is monitored to ensure that it is only provided to relevant persons. Research prepared by SCP is not intended to be received and/or used by any person who is categorised as a retail client under COBS.

STANFORD CAPITAL PARTNERS – KEY CONTACTS

RESEARCH

Mike Jeremy
+44 (0) 20 3650 3650
mjeremy@stanfordcp.co.uk

CORPORATE BROKING

Bob Pountney
+44 (0) 20 3650 3651
bpountney@stanfordcp.co.uk

Patrick Claridge
+44 (0) 20 3650 3650
pclaridge@stanfordcp.co.uk